Condition: Ovarian Cancer · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
This description comes directly from the study's public registry record.
Shuni Wang · +86 021-61053363 · shuni.wang@hengrui.com
Di Zong · +86 021-61053363 · di.zong@hengrui.com
Always discuss trial participation with your own doctor first.
| National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06394492